Almirall Expands Lebrikizumab into Nummular Eczema with Phase III Trial
Event summary
- Almirall to initiate Phase III trial (LumiNE) for lebrikizumab in nummular eczema H1 2026.
- Study will enroll ~270 patients across 60 European centers, with potential expansion.
- Lebrikizumab targets IL-13 cytokine, previously approved for atopic dermatitis.
- Nummular eczema affects 0.1%–9% of population, with higher prevalence in older adults.
The big picture
Almirall's pivot to nummular eczema reflects broader industry efforts to expand biologics into related dermatological conditions. The trial leverages lebrikizumab's proven IL-13 mechanism, targeting a condition with limited treatment options. Success could position Almirall as a leader in medical dermatology, while failure risks diluting focus from core atopic dermatitis market.
What we're watching
- Clinical Success
- Whether lebrikizumab's efficacy in atopic dermatitis translates to nummular eczema.
- Regulatory Pathway
- The timeline for potential approval in this new indication.
- Market Expansion
- How Almirall positions lebrikizumab against competitors in dermatology.
Related topics